1
|
Greef B and Eisen T: Medical treatment of
renal cancer: New horizons. Br J Cancer. 115:505–516. 2016.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Shoji S, Nakano M, Sato H, Tang XY,
Osamura YR, Terachi T, Uchida T and Takeya K: The current status of
tailor-made medicine with molecular biomarkers for patients with
clear cell renal cell carcinoma. Clin Exp Metastasis. 31:111–134.
2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bhatt JR and Finelli A: Landmarks in the
diagnosis and treatment of renal cell carcinoma. Nat Rev Urol.
11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
DiDonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Bradford JW and Baldwin AS: IKK/nuclear
factor-kappaB and oncogenesis: Roles in tumor-initiating cells and
in the tumor microenvironment. Adv Cancer Res. 121:125–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Morais C, Gobe G, Johnson DW and Healy H:
The emerging role of nuclear factor kappa B in renal cell
carcinoma. Int J Biochem Cell Biol. 43:1537–1549. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
DiDonato JA, Hayakawa M, Rothwarf DM,
Zandi E and Karin M: A cytokine-responsive IkappaB kinase that
activates the transcription factor NF-kappaB. Nature. 388:548–554.
1997. View Article : Google Scholar : PubMed/NCBI
|
10
|
Li ZW, Chu W, Hu Y, Delhase M, Deerinck T,
Ellisman M, Johnson R and Karin M: The IKKbeta subunit of IkappaB
kinase (IKK) is essential for nuclear factor kappaB activation and
prevention of apoptosis. J Exp Med. 189:1839–1845. 1999. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tanaka M, Fuentes ME, Yamaguchi K, Durnin
MH, Dalrymple SA, Hardy KL and Goeddel DV: Embryonic lethality,
liver degeneration, and impaired NF-kappa B activation in
IKK-beta-deficient mice. Immunity. 10:421–429. 1999. View Article : Google Scholar : PubMed/NCBI
|
12
|
Erstad DJ and Cusack JC Jr: Targeting the
NF-κB pathway in cancer therapy. Surg Oncol Clin N Am. 22:705–746.
2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Xia Y, Padre RC, De Mendoza TH, Bottero V,
Tergaonkar VB and Verma IM: Phosphorylation of p53 by IkappaB
kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci
USA. 106:2629–26234. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang
F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase
promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell.
117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Cummins EP, Berra E, Comerford KM,
Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE,
Moynagh P, Pouyssegur J and Taylor CT: Prolyl hydroxylase-1
negatively regulates IKappaB kinase-beta, giving insight into
hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA.
103:18154–18159. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wang Y, Zhao W, Gao Q, Fan L, Qin Y, Zhou
H, Li M and Fang J: pVHL mediates K63-linked ubiquitination of
IKKβ, leading to IKKβ inactivation. Cancer Lett. 383:1–8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: Kidney. American Joint Committee
on Cancer: AJCC Cancer Staging Manual. 6th. Springer; New York, NY:
pp. 323–328. 2002
|
18
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sliwinska-Jewsiewicka A, Kowalczyk AE,
Krazinski BE, Godlewski J, Kwiatkowski P, Kiewisz J, Grzegrzolka J,
Dziegiel P and Kmiec Z: Decreased expression of SATB2 associates
with tumor growth and predicts worse outcome in patients with clear
cell renal cell carcinoma. Anticancer Res. 38:839–846.
2018.PubMed/NCBI
|
20
|
Kowalczyk AE, Krazinski BE, Godlewski J,
Grzegrzolka J, Kiewisz J, Kwiatkowski P, Sliwinska-Jewsiewicka A,
Dziegiel P and Kmiec Z: SATB1 is down-regulated in clear cell renal
cell carcinoma and correlates with MIR-21-5p overexpression and
poor prognosis. Cancer Genomics Proteomics. 13:209–217.
2016.PubMed/NCBI
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Kowalczyk AE, Krazinski BE, Godlewski J,
Kiewisz J, Kwiatkowski P, Sliwinska-Jewsiewicka A, Kiezun J,
Wierzbicki PM, Bodek G, Sulik M and Kmiec Z: Altered expression of
the PLAGL1 (ZAC1/LOT1) gene in colorectal cancer: Correlations to
the clinicopathological parameters. Int J Oncol. 47:951–962. 2015.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Kowalczyk AE, Godlewski J, Krazinski BE,
Kiewisz J, Sliwinska-Jewsiewicka A, Kwiatkowski P, Pula B, Dziegiel
P, Janiszewski J, Wierzbicki PM and Kmiec Z: Divergent expression
patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and
normal tissues. Tumor Biol. 36:4441–4452. 2015. View Article : Google Scholar
|
24
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
25
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Peri S, Devarajan K, Yang DH, Knudson AG
and Balachandran S: Meta-analysis identifies NF-κB as a therapeutic
target in renal cancer. PLoS One. 8:e767462013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Qi H and Ohh M: The von Hippel-Lindau
tumor suppressor protein sensitizes renal cell carcinoma cells to
tumor necrosis factor-induced cytotoxicity by suppressing the
nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res.
63:7076–7080. 2003.PubMed/NCBI
|
28
|
Nowicka AM, Häuselmann I, Borsig L,
Bolduan S, Schindler M, Schraml P, Heikenwalder M and Moch H: A
novel pVHL-independent but NEMO-driven pathway in renal cancer
promotes HIF stabilization. Oncogene. 35:3125–3138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Gamble C, McIntosh K, Scott R, Ho KH,
Plevin R and Paul A: Inhibitory kappa B kinases as targets for
pharmacological regulation. Br J Pharmacol. 165:802–819. 2012.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Morais C, Pat B, Gobe G, Johnson DW and
Healy H: Pyrrolidine dithiocarbamate exerts anti-proliferative and
pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol
Dial Transplant. 21:3377–3388. 2006. View Article : Google Scholar : PubMed/NCBI
|
31
|
Morais C, Gobe G, Johnson DW and Healy H:
Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear
factor kappa B inhibitor. Angiogenesis. 12:365–379. 2009.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Morais C, Gobe G, Johnson DW and Healy H:
Inhibition of nuclear factor kappa B transcription activity drives
a synergistic effect of pyrrolidine dithiocarbamate and cisplatin
for treatment of renal cell carcinoma. Apoptosis. 15:412–425. 2010.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Morais C, Healy H, Johnson DW and Gobe G:
Inhibition of nuclear factor kappa B attenuates tumour progression
in an animal model of renal cell carcinoma. Nephrol Dial
Transplant. 25:1462–1474. 2010. View Article : Google Scholar : PubMed/NCBI
|
34
|
Brzóska K, Sochanowicz B, Siomek A,
Olinski R and Kruszewski M: Alterations in the expression of genes
related to NF-κB signaling in liver and kidney of CuZnSOD-deficient
mice. Mol Cell Biochem. 353:151–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
35
|
Bera A, Ghosh-Choudhury N, Dey N, Das F,
Kasinath BS, Abboud HE and Choudhury GG: NFκB-mediated cyclin D1
expression by microRNA-21 influences renal cancer cell
proliferation. Cell Signal. 25:2575–2586. 2013. View Article : Google Scholar : PubMed/NCBI
|
36
|
Bera A, Das F, Ghosh-Choudhury N, Kasinath
BS, Abboud HE and Choudhury GG: microRNA-21-induced dissociation of
PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate
renal cancer cell invasion. Exp Cell Res. 328:99–117. 2014.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H,
Lv T, Zhang H, Liu L, An H, et al: Sunitinib induces cellular
senescence via p53/Dec1 activation in renal cell carcinoma cells.
Cancer Sci. 104:1052–1061. 2013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Kim HJ, Hawke N and Baldwin AS: NF-kappaB
and IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
39
|
Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi
J, Wang X and Sun B: High expression levels of IKKalpha and IKKbeta
are necessary for the malignant properties of liver cancer. Int J
Cancer. 126:1263–1274. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Romieu-Mourez R, Landesman-Bollag E,
Seldin DC, Traish AM, Mercurio F and Sonenshein GE: Roles of IKK
kinases and protein kinase CK2 in activation of nuclear
factor-kappaB in breast cancer. Cancer Res. 61:3810–3818.
2001.PubMed/NCBI
|
41
|
Mieczkowski J, Kocyk M, Nauman P,
Gabrusiewicz K, Sielska M, Przanowski P, Maleszewska M, Rajan WD,
Pszczolkowska D, Tykocki T, et al: Down-regulation of IKKβ;
expression in glioma-infiltrating microglia/macrophages is
associated with defective inflammatory/immune gene responses in
glioblastoma. Oncotarget. 6:33077–33090. 2015. View Article : Google Scholar : PubMed/NCBI
|